Journal of Hematology & Oncology

Papers
(The H4-Index of Journal of Hematology & Oncology is 88. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans653
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024630
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018625
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma622
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency586
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and548
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening415
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China384
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ358
Cancer vaccines: current status and future directions350
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects347
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies339
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy330
Landscape of biallelic DNMT3A mutant myeloid neoplasms317
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2310
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients263
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression263
Integrated proteogenomic analysis revealed the metabolic heterogeneity in noncancerous liver tissues of patients with hepatocellular carcinoma262
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts259
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis253
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma246
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)231
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation205
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration205
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors202
Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis201
Recent advances in therapeutic strategies for non-small cell lung cancer195
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p191
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway189
Personalized nanovaccines for treating solid cancer metastases189
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1186
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis176
Ferroptosis: principles and significance in health and disease176
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis173
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model170
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study170
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs165
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer165
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global 162
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?160
3D chromatin architecture and transcription regulation in cancer153
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy151
Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology150
The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers148
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia138
Development of a novel combined nomogram model integrating deep learning-pathomics, radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients138
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation136
Small RNA modifications: regulatory molecules and potential applications136
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response134
Recent advances in targeted strategies for triple-negative breast cancer134
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting134
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages131
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study129
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study129
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation125
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia125
Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure125
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies125
Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma124
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer122
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers121
A single-cell and spatially resolved atlas of human osteosarcomas120
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry120
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects117
Target neutrophil heterogeneity and plasticity in cancer116
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment115
A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth112
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting110
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts109
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype109
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives107
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia107
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis106
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting105
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies104
Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee104
The functional and clinical roles of liquid biopsy in patient-derived models103
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer100
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting100
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia99
Challenges and new technologies in adoptive cell therapy97
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia97
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives94
Worked to the bone: antibody-based conditioning as the future of transplant biology93
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting91
Echinomycin as a promising therapeutic agent against KSHV-related malignancies90
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function89
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting89
0.24434494972229